A director gains 3,323 units payable in stock after his service ends at DENTSPLY SIRONA (XRAY).
DENTSPLY SIRONA director Jonathan Jay Mazelsky acquired 3,323 phantom stock units on September 30, 2026, priced at $9.03 per share. These units are economically equivalent to common shares and will become payable in common stock upon the termination of his directorship. After this grant, Mazelsky's direct phantom-stock balance stands at 23,345 units.
DS World UK returns to Birmingham
DS World UK has returned to Birmingham at The Vox at the NEC, attracting over 500 participants for two days of clinical education, product demonstrations, and professional exchange. The event features more than 40 sessions and workshops covering various dental topics, including implantology, orthodontics, and digital dentistry. Keynote speaker Jez Rose is addressing mindset and environmental influences on outcomes, while an exhibition area provides networking opportunities and a showcase for dental technologies.
DENTSPLY SIRONA (NASDAQ:XRAY) Reaches New 1-Year Low - Here's Why
DENTSPLY SIRONA (NASDAQ:XRAY) shares recently hit a new 52-week low of $8.77, declining 2.5% amid broader investor concerns. Despite beating quarterly earnings and revenue estimates, the company reported a 4.1% year-over-year revenue decline and a negative net margin of 14.99%. Analyst sentiment for the stock remains neutral with a consensus "Hold" rating and an average price target of $13.31, significantly above its current trading level.
ETFs Investing in DENTSPLY SIRONA, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold DENTSPLY SIRONA, Inc. (DY2) stocks. The list, sorted by market value, includes details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, change, and 3-year NAV total return for each ETF. It highlights how ETFs make investing in stocks more accessible while offering diversification and lower risk.
Impressions from DS World Las Vegas 2026
DS World Las Vegas 2026 convened dental professionals globally, offering over 60 hands-on training opportunities and up to 15 continuing education credits. The event showcased Dentsply Sirona's latest technological advancements, including the DS Core platform and Primescan 2. Attendees explored established and upcoming dental solutions in the exhibition area and benefited from a diverse speaker lineup across various educational tracks.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Stock Rated "Hold" by Sell-Side Analysts
Sell-side analysts have given DENTSPLY SIRONA Inc. (NASDAQ:XRAY) an average "Hold" rating, with a consensus 12-month price target of $13.31. Institutional investors own 95.70% of the company, and despite beating EPS and revenue estimates in its last quarter, the stock opened near its 52-week low and remains below its moving averages. The company reported a 4.1% year-over-year revenue decline and a negative net margin.
Dentsply Sirona stock hits 52-week low at 9.35 USD
Dentsply Sirona (XRAY) stock has fallen to a 52-week low of $9.35, marking a 24.88% decline over the past year. Despite market challenges, InvestingPro analysis suggests the stock is undervalued with potential upside, predicting profitability this year and noting an attractive 6.72% dividend yield. The company recently reported Q2 revenue slightly above estimates and is implementing a "Return-to-Growth" plan to improve performance.
Dentsply Sirona stock hits 52-week low at 9.35 USD By Investing.com
Dentsply Sirona Inc.'s stock has fallen to a 52-week low of $9.35, just above its $9.36 floor, representing a 24.88% decline over the past year. Despite the downturn, InvestingPro analysis suggests the stock is undervalued with potential for upside, and analysts predict profitability this year, coupled with an attractive 6.72% dividend yield. The company recently reported Q2 revenue slightly above estimates but still faces challenges, pursuing a "Return-to-Growth" plan to improve performance.
Q2 Rundown: Dentsply Sirona (NASDAQ:XRAY) Vs Other Dental Equipment & Technology Stocks
This article analyzes the Q2 performance of several dental equipment and technology stocks, highlighting Dentsply Sirona (XRAY), Envista (NVST), Align Technology (ALGN), and Henry Schein (HSIC). It details their revenue growth, performance against analyst estimates, and stock price reactions, noting that the sector experienced strong Q2 revenues but subsequent stock price declines. The piece also touches on broader market shifts, including concerns over AI and geopolitics impacting investor focus.
Bank of America Corp DE Makes New Investment in DENTSPLY SIRONA Inc. $XRAY
Bank of America Corp DE has acquired 2.92 million shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY), valued at approximately $31 million, marking a new 1.47% stake in the company. Institutional investors collectively hold 95.7% of DENTSPLY SIRONA's stock, with several firms increasing or initiating positions. Despite analysts maintaining a "Hold" rating with a target price of $13.31, the medical instruments supplier recently beat quarterly earnings estimates but experienced a 4.1% year-over-year revenue decline.
Dentsply Sirona stock gains 5.40 percent as earnings beat estimates
Dentsply Sirona (DENT) stock rose 5.40 percent to USD 9.95 on September 22, 2026, driven by second-quarter EPS of USD 0.52, which significantly beat the estimated USD 0.35. Despite this earnings beat, revenue declined 4.1 percent year-over-year, and the stock remains near its 52-week low and below its 200-day moving average. The market is now focused on whether the improved earnings can lead to renewed sales growth.
Squarepoint Ops LLC Sells 431,734 Shares of DENTSPLY SIRONA Inc. $XRAY
Squarepoint Ops LLC significantly reduced its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by selling 431,734 shares, retaining 55,600 shares valued at approximately $590,000. Despite beating EPS estimates, the medical instruments supplier's revenue declined year-over-year. Analysts currently hold a consensus "Hold" rating for XRAY with an average target price of $13.31.
DENTSPLY SIRONA (NASDAQ:XRAY) Reaches New 1-Year Low - Time to Sell?
DENTSPLY SIRONA (NASDAQ:XRAY) stock recently hit a new 52-week low of $9.36. Despite exceeding quarterly EPS and revenue estimates, the company experienced a 4.1% year-over-year revenue decline and a negative net margin. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $13.31, while institutional investors hold a significant majority of the stock.
Dentsply Sirona Inc stock hits 52-week low at 9.4 USD By Investing.com
Dentsply Sirona Inc. stock has reached a 52-week low at $9.40, marking a significant decline of 29.51% over the past year and trading 36% below its 52-week high. Despite this downturn, InvestingPro analysis suggests the stock is undervalued with a Fair Value of $13.77 and offers a substantial 6.31% dividend yield, maintained for 32 consecutive years. The company recently reported Q2 revenue slightly above estimates but experienced a year-over-year sales decline, and while maintaining full-year guidance, anticipates a weaker Q3 before expected improvement.
Dentsply Sirona Inc stock hits 52-week low at 9.4 USD
Dentsply Sirona Inc. (XRAY) stock has reached a 52-week low of $9.40, reflecting a 29.51% decline over the past year. Despite this, InvestingPro analysis suggests the company is undervalued, with a fair value of $13.77, and it offers a substantial 6.31% dividend yield, maintaining payments for 32 consecutive years. The company recently surpassed second-quarter revenue estimates but experienced a year-over-year sales decline, continuing its "Return-to-Growth" plan to address market challenges.
Dentsply Sirona Inc stock hits 52-week low at 9.4 USD
Dentsply Sirona Inc. (XRAY) stock has hit a 52-week low at $9.40, reflecting a 29.51% decline over the past year and trading 36% below its 52-week high. Despite this, InvestingPro analysis suggests the stock is undervalued with a fair value of $13.77, and the company offers a substantial 6.31% dividend yield, having maintained payments for 32 consecutive years. The company recently reported Q2 revenue of $898 million, slightly exceeding estimates, but sales declined year-over-year, while operating cash flow increased significantly.
DENTSPLY SIRONA Inc. $XRAY Stock Holdings Decreased by Amundi
Amundi significantly reduced its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 85.6% in the second quarter, selling over 240,000 shares. Despite this, institutional investors collectively own approximately 95.7% of the company's stock, with several other funds either initiating or increasing their positions. Analysts currently have a consensus "Hold" rating on XRAY with an average price target of $13.54, even though the company recently beat EPS and revenue estimates while experiencing a year-over-year revenue decline.
Robbins Geller Rudman & Dowd LLP Announces Pending Class Action Lawsuit in the Dentsply Securities Litigation
Robbins Geller Rudman & Dowd LLP has announced a pending class action lawsuit against Dentsply Sirona Inc., Ann Casey, and Jorge Gomez. The lawsuit, filed in the U.S. District Court for the Southern District of New York, has been certified as a class action for individuals who purchased Dentsply Sirona common stock between June 9, 2021, and November 13, 2022. Class members have until October 19, 2026, to request exclusion from the class if they do not wish to be bound by the lawsuit's proceedings.
VIRGINIA RETIREMENT SYSTEMS ET Al Acquires New Holdings in DENTSPLY SIRONA Inc. $XRAY
Virginia Retirement Systems acquired 225,700 shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the second quarter, valued at approximately $2.4 million. This new holding represents about 0.11% of the company, which continues to see high institutional ownership at 95.7%. Despite a recent revenue decline, DENTSPLY SIRONA beat quarterly EPS estimates, and analysts maintain a consensus "Hold" rating with a target price of $13.54.
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 182,661 Shares of DENTSPLY SIRONA Inc. $XRAY
UBS Asset Management Americas LLC has reduced its stake in DENTSPLY SIRONA Inc. by selling 182,661 shares, retaining 452,599 shares valued at approximately $4.8 million. Despite beating earnings and revenue estimates in the last quarter, the company's stock has an average "Hold" rating from analysts with a consensus price target of $13.54, trading near its one-year low. Institutional investors collectively own 95.7% of the medical instruments supplier.
DENTSPLY SIRONA (XRAY) Returns To Profit As Investors Weigh Its Valuation
DENTSPLY SIRONA (XRAY) has returned to profitability in Q2 2026 despite a 4.1% year-over-year decline in net sales. The company's shares have shown choppy performance, with short-term gains contrasting with significant long-term losses. Analysts view the stock as 14.7% undervalued, with a fair value of $13.40, driven by expectations of expanding digital dentistry platforms and improved margins.
The Manufacturers Life Insurance Company Takes Position in DENTSPLY SIRONA Inc. $XRAY
The Manufacturers Life Insurance Company has acquired a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY), purchasing 184,321 shares valued at approximately $1.96 million. Institutional investors collectively own 95.7% of the company, while insiders recently bought 35,160 shares worth about $351,179. Despite mixed analyst sentiment and a "Hold" rating, the company exceeded recent quarterly EPS and revenue expectations.
Does XRAY’s Profit Recovery and Reaffirmed 2026 Outlook Shift the Dentsply Sirona Thesis?
Dentsply Sirona (XRAY) reported Q2 2026 results showing a net sales decline but a return to net income, improved margins, and stronger cash generation, while reaffirming its full-year 2026 guidance. This shift towards profitability and focus on efficiency is being evaluated to see if it changes the investment narrative for the company. The article discusses whether these improvements can offset revenue pressure and past return issues, with the reiterated guidance serving as a key short-term catalyst.
Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference
Dentsply Sirona announced its participation in the Baird 2026 Global Healthcare Conference, with management scheduled to present on Tuesday, September 15, 2026, at 11:25 a.m. ET. Investors can access a live audio webcast and replay through the Investors section of the company's website. Dentsply Sirona, a leading manufacturer of dental products and technologies, is headquartered in Charlotte, N.C., and its shares are listed on Nasdaq under the symbol XRAY.
Dentsply Sirona to Participate in the Baird 2026 Global Healthcare Conference
Dentsply Sirona (Nasdaq: XRAY) announced its participation in the Baird 2026 Global Healthcare Conference, with management scheduled to present on September 15, 2026, at 11:25 a.m. ET. A live audio webcast and replay will be available on the company's investor relations website. Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies.
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Consensus Rating of "Hold" from Analysts
Analysts have assigned DENTSPLY SIRONA (NASDAQ:XRAY) an average "Hold" rating, with a consensus 12-month price target of $13.54, which is higher than its current price of $10.76. Despite beating EPS and revenue expectations in its latest quarter, the company saw a 4.1% year-over-year revenue decline and reported a negative net margin. Insider and institutional buying activity was noted, with institutions collectively owning 95.70% of the stock.
Bank of New York Mellon Corp Makes New Investment in DENTSPLY SIRONA Inc. $XRAY
Bank of New York Mellon Corp has acquired 1.55 million shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) valued at approximately $16.4 million, representing 0.77% of the company's stock, with institutional investors collectively owning 95.7% of the shares. DENTSPLY SIRONA recently exceeded earnings expectations, reporting $0.52 EPS against a $0.35 consensus, though revenue saw a 4.1% year-over-year decline. Analysts generally hold a "Hold" rating on the stock, with an average target price of $13.54 compared to its current $11.17, while company insiders have also made significant share purchases in recent months.
DENTSPLY SIRONA Inc (DY2) Q4 2025 Earnings Report - Results, Call & Slides
DENTSPLY SIRONA Inc. (CH:DY2) reported its Q4 2025 earnings, with actual EPS matching the consensus at CHF0.22, but missing the consensus by less than CHF0.01 compared to the one-year-ago EPS of CHF0.21. The company's revenue beat expectations, coming in at CHF771.97M against an expected CHF743.98M, marking a 6.19% year-over-year growth. The earnings announcement took place on February 26, 2026, after market close, with the next earnings date estimated for October 29, 2026.
Zacks Research Forecasts Weaker Earnings for DENTSPLY SIRONA
Zacks Research has lowered its Q3 2026 EPS forecast for DENTSPLY SIRONA (NASDAQ:XRAY) to $0.31 from $0.37, while its full-year 2026 estimate stands at $1.50 per share, aligning with the company's guidance. Analyst sentiment remains cautious with a consensus "Hold" rating and an average price target of $13.54, despite the company recently exceeding quarterly earnings and revenue expectations. The stock is currently trading below its 50-day and 200-day moving averages, and insiders have recently increased their holdings.
Deutsche Bank AG Makes New Investment in DENTSPLY SIRONA Inc. $XRAY
Deutsche Bank AG has initiated a new investment in DENTSPLY SIRONA Inc. (NASDAQ:XRAY), acquiring 267,407 shares valued at approximately $2.84 million. This move is part of broader institutional investor activity, with hedge funds and institutions collectively owning 95.70% of the company. Despite recent insider purchases and beating quarterly EPS and revenue estimates, analysts maintain a consensus "Hold" rating for DENTSPLY SIRONA due to a year-over-year revenue decline and negative net margin.
SDI Limited Initiates Recall of Dentsply Sirona Capsule Mixer Model No. 5546068
SDI Limited has initiated a Class II voluntary recall of 1,444 units of the Dentsply Sirona Capsule Mixer Model No. 5546068. The recall is due to a potential for electrical discharge from the unit when unplugged. The recall is ongoing and impacts various US states.
26,711,079 Shares in DENTSPLY SIRONA Inc. $XRAY Acquired by BlackRock Inc.
BlackRock Inc. has acquired 26,711,079 shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY), valued at approximately $283.4 million, establishing a 13.33% stake in the company. This acquisition makes BlackRock a significant institutional investor in the medical instruments supplier, alongside other hedge funds and institutional investors who collectively own 95.70% of the company's stock. Despite a "Hold" consensus rating from analysts and a recent decline in year-over-year revenue, DENTSPLY SIRONA exceeded quarterly EPS expectations.
DENTSPLY SIRONA : New One-Year Clinical Data Demonstrates Predictable Performance of the PrimeTaper EV Implant System
Dentsply Sirona announced positive one-year clinical data for its PrimeTaper EV implant system, showing a 98.5% implant survival rate and minimal marginal bone loss. The multicenter study, involving 136 patients across five countries, reinforces the company's commitment to evidence-based implant design. These results highlight the predictable performance and stability of the PrimeTaper EV system, building on Dentsply Sirona's four decades of clinical research in implant dentistry.
Ieq Capital LLC Invests $1.87 Million in DENTSPLY SIRONA Inc. $XRAY
Ieq Capital LLC has acquired a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the second quarter, purchasing 176,516 shares valued at approximately $1.87 million. This makes Ieq Capital LLC a 0.09% owner of the medical instruments supplier. Other institutional investors have also adjusted their holdings in the company, which recently reported stronger-than-expected quarterly earnings and has insider buying activity.
Paradigm Capital Management Inc. NY Makes New $39.77 Million Investment in DENTSPLY SIRONA Inc. $XRAY
Paradigm Capital Management Inc. NY has initiated a new $39.77 million investment in DENTSPLY SIRONA Inc., acquiring 3.75 million shares and representing 1.88% of the company. This makes DENTSPLY SIRONA its 21st largest position, comprising 1.1% of Paradigm Capital Management's portfolio. Despite a recent quarterly revenue decline, DENTSPLY SIRONA exceeded earnings expectations with $0.52 per share and maintains a "Hold" consensus rating among analysts.
Cibc World Market Inc. Takes Position in DENTSPLY SIRONA Inc. $XRAY
Cibc World Market Inc. has acquired a new position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY), purchasing 1.35 million shares valued at approximately $14.3 million, giving them a 0.68% stake. The medical instruments supplier recently reported strong quarterly earnings of $0.52 EPS, beating analyst expectations, though revenue saw a slight year-over-year decline. Despite positive insider buying activity, analysts maintain a "Hold" rating on the stock with a consensus price target of $13.54.
XRAY 6-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages DENTSPLY SIRONA Inc. (XRAY) Investors with Over $1 Million Losses to Contact Firm's Attorneys, Securities Class Action Pending
Hagens Berman, a national trial law firm, is urging investors of DENTSPLY SIRONA Inc. (XRAY) who have incurred losses exceeding $1 million to contact their attorneys. A securities fraud class action has been filed, alleging that DENTSPLY inflated revenues and earnings through accounting manipulation related to a distributor rebate program to benefit senior executives. Investors learned of the alleged misconduct following the termination of CEO Donald M. Casey Jr. and an internal investigation into the company's use of incentives and executive compensation targets.
1,167,350 Shares in DENTSPLY SIRONA Inc. $XRAY Acquired by Heartland Advisors Inc.
Heartland Advisors Inc. has acquired a new stake of 1,167,350 shares in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the second quarter, valued at approximately $12.39 million. This makes Heartland Advisors Inc. a significant institutional investor, owning about 0.59% of the medical instruments supplier's stock. Other institutional investors have also adjusted their positions, and company insiders have recently purchased additional shares.
Edmond DE Rothschild Holding S.A. Purchases Shares of 4,503,300 DENTSPLY SIRONA Inc. $XRAY
Edmond DE Rothschild Holding S.A. has acquired a new stake of 4,503,300 shares in DENTSPLY SIRONA Inc., valued at approximately $47.8 million, representing a 2.26% ownership. This move comes as institutional investors now hold 95.7% of the company's stock, and DENTSPLY SIRONA insiders have also recently increased their holdings. The company recently surpassed quarterly earnings expectations but reported a decline in year-over-year revenue, while analysts maintain a consensus "Hold" rating with a target price of $13.38.
Wellspect Launches Surity Urinary Management System | XRAY Stock News
Wellspect HealthCare, a subsidiary of Dentsply Sirona (NASDAQ: XRAY), has launched the Surity™ Urinary Management System in the U.S. This discreet at-home urine collection device is designed to help more than 13 million Americans and their caregivers manage urinary incontinence, complementing the existing Surity™ Female and Male External Catheters. The system offers gentle suction, quiet operation, and carbon filters for odor reduction, aiming to improve comfort and rest, particularly for nighttime use.
DENTSPLY SIRONA Inc. $XRAY Shares Purchased by Bank of America Corp DE
Bank of America Corp DE increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 18.3% in the first quarter, now owning 2.43 million shares valued at $28.2 million. The company reported strong Q1 earnings, beating analyst expectations with $0.52 EPS and $898 million in revenue, despite a 4.1% year-over-year revenue decline. Analysts currently maintain a "Hold" rating on the stock with an average price target of $13.38.
Royal Bank of Canada Raises Holdings in DENTSPLY SIRONA Inc. $XRAY
Royal Bank of Canada significantly increased its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 137.7% in the first quarter, now owning 256,701 shares valued at approximately $3.0 million. Other institutional investors have also adjusted their holdings, and company insiders recently purchased shares. DENTSPLY SIRONA exceeded quarterly earnings expectations with $0.52 EPS, though revenue saw a slight year-over-year decrease.
DENTSPLY Sirona Inc (XRAY) News, Articles, Events & Latest Updates
DENTSPLY Sirona Inc. (XRAY) reported a Q2 2026 profit, turning around from a loss in the previous year, driven by improved margins and the absence of prior impairment charges. Despite a 4.1% sales decline due to dental weakness, the company's Wellspect division showed growth, and its full-year 2026 guidance was reaffirmed. The article also includes various news items and earnings reports related to XRAY and other companies like Align Technology (ALGN), Envista (NVST), and McKesson (MCK).
Dentsply Sirona (XRAY): Southpoint reports 7M-share, 3.5% ownership in 13G/A
Southpoint Master Fund and its affiliates, including John S. Clark II, have reported a beneficial ownership of 7,000,000 shares, representing a 3.5% stake in Dentsply Sirona Inc. (XRAY). This disclosure was made in an amended Schedule 13G/A filing, indicating shared voting and dispositive power over the shares. The ownership percentage is based on 199,353,876 shares outstanding as of July 24, 2026.
Is DENTSPLY SIRONA’s (XRAY) Steady Buyback and Reaffirmed Outlook Reframing Its Risk‑Reward Profile?
DENTSPLY SIRONA Inc. reported mixed Q2 2026 results with lower year-on-year sales but a return to net income, reaffirming its full-year 2026 net sales guidance. The company continued its share buyback program while navigating market expectations that are slightly above its own reaffirmed revenue outlook. The article suggests investors assess whether the company's turnaround strategy, digital platform investments, and share repurchases will effectively address execution risks and drive future growth towards its projected 2029 revenue and earnings targets.
Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript
Dentsply Sirona reported Q2 2026 results with a revenue decline of 4.1% and adjusted EPS flat year-over-year at $0.52, benefiting from a $0.17 per share tariff refund. The company is six months into a 24-month restructuring program focused on customer re-engagement, commercial realignment, and financial discipline, with new CFO John C. Fortson emphasizing operational excellence and debt reduction. While maintaining full-year revenue and adjusted EPS guidance, management expects Q3 revenue to decline sequentially due to seasonality and earnings to be below Q2 levels, excluding the tariff refund.
Is DENTSPLY SIRONA’s (XRAY) Steady Buyback and Reaffirmed Outlook Reframing Its Risk‑Reward Profile?
DENTSPLY SIRONA (XRAY) reported Q2 2026 sales of US$898 million, returning to a net income of US$37 million, and reaffirmed its full-year 2026 sales guidance of US$3.5 billion to US$3.6 billion, despite lower year-on-year revenue. The company continued its share buyback program, repurchasing 1.3 million shares for US$12.92 million. This mixed performance, coupled with the reaffirmed guidance, necessitates a reassessment of the company's investment narrative, particularly concerning its turnaround strategy and the impact of revenue pressures on profitability.
DENTSPLY SIRONA (XRAY) gains AQR Capital as 5.22% beneficial owner
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have reported a 5.22% beneficial ownership in DENTSPLY SIRONA Inc. (XRAY), amounting to 10,458,771 shares. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment with shared voting and dispositive power over all shares. The filing details the entities' beneficial ownership, which is not intended to change or influence the control of the issuer.
DS World Las Vegas 2026 connects clinical and laboratory education
Dentsply Sirona World Las Vegas 2026 will offer a comprehensive educational program for dental professionals, connecting clinical expertise, laboratory innovation, and digital workflows to advance patient care. The event, taking place from September 24 to 26, will feature main stage presentations by clinical experts and a dedicated laboratory track with hands-on training and lectures. Attendees can earn continuing education credits, network, and explore the latest innovations in connected dentistry.
The 5 Most Interesting Analyst Questions From Dentsply Sirona’s Q2 Earnings Call
Dentsply Sirona (XRAY) reported Q2 CY2026 earnings, exceeding analyst expectations for revenue and adjusted EPS, though shares declined post-announcement. Management attributed revenue decline to lower sales in key segments and regions, noting the company is in a "turnaround" phase with uneven improvements. Analysts focused on the executive team's readiness, specifics of the growth plan, impact of tariff refunds, U.S. commercial team buildout, and softness in the OIS segment.
